[{"address1": "2051 Ringwood Avenue", "city": "San Jose", "state": "CA", "zip": "95131", "country": "United States", "phone": "408 457 3700", "website": "https://www.ranitherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.", "fullTimeEmployees": 140, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mir A. Imran", "age": 68, "title": "Executive Chairman", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 80000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Talat  Imran", "age": 42, "title": "CEO & Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 450000, "exercisedValue": 0, "unexercisedValue": 9180}, {"maxAge": 1, "name": "Mr. Svai S. Sanford", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 416000, "exercisedValue": 0, "unexercisedValue": 5173}, {"maxAge": 1, "name": "Dr. Mir  Hashim", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 416000, "exercisedValue": 0, "unexercisedValue": 5427}, {"maxAge": 1, "name": "Mr. Alireza  Javadi", "title": "Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Groen J.D.", "age": 53, "title": "General Counsel", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Bella  Vazquez", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kate  McKinley M.B.A.", "age": 47, "title": "Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Arvinder  Dhalla", "title": "Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.84, "open": 1.86, "dayLow": 1.76, "dayHigh": 1.9002, "regularMarketPreviousClose": 1.84, "regularMarketOpen": 1.86, "regularMarketDayLow": 1.76, "regularMarketDayHigh": 1.9002, "beta": 0.165, "forwardPE": -2.3780143, "volume": 658443, "regularMarketVolume": 658443, "averageVolume": 1066269, "averageVolume10days": 4139420, "averageDailyVolume10Day": 4139420, "bid": 1.84, "ask": 1.93, "bidSize": 200, "askSize": 400, "marketCap": 108318240, "fiftyTwoWeekLow": 1.24, "fiftyTwoWeekHigh": 8.75, "fiftyDayAverage": 1.5195, "twoHundredDayAverage": 2.899555, "currency": "USD", "enterpriseValue": 67609352, "floatShares": 20715116, "sharesOutstanding": 33311500, "sharesShort": 1893158, "sharesShortPriorMonth": 1491988, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.056799997, "heldPercentInsiders": 0.27313, "heldPercentInstitutions": 0.17013, "shortRatio": 7.38, "shortPercentOfFloat": 0.094, "impliedSharesOutstanding": 58550400, "bookValue": 0.105, "priceToBook": 17.61905, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -28169000, "trailingEps": -1.05, "forwardEps": -1.01, "enterpriseToEbitda": -1.331, "52WeekChange": -0.4390244, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "RANI", "underlyingSymbol": "RANI", "shortName": "Rani Therapeutics Holdings, Inc", "longName": "Rani Therapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "5ed5bf18-2fc9-357f-8d44-03f1c0fe19bf", "messageBoardId": "finmb_242425883", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.85, "targetHighPrice": 17.0, "targetLowPrice": 8.0, "targetMeanPrice": 11.5, "targetMedianPrice": 10.5, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 30404000, "totalCashPerShare": 0.913, "ebitda": -50801000, "totalDebt": 33732000, "quickRatio": 1.504, "currentRatio": 1.602, "debtToEquity": 584.104, "returnOnAssets": -0.56799, "returnOnEquity": -2.7056699, "freeCashflow": -18851876, "operatingCashflow": -39319000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]